These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36243940)

  • 1. HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs.
    Valdez BC; Nieto Y; Yuan B; Murray D; Andersson BS
    Oncotarget; 2022 Oct; 13():1122-1135. PubMed ID: 36243940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.
    Valdez BC; Tsimberidou AM; Yuan B; Nieto Y; Baysal MA; Chakraborty A; Andersen CR; Andersson BS
    Oncotarget; 2024 Jun; 15():361-373. PubMed ID: 38829622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
    Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
    EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations.
    Valdez BC; Tsimberidou AM; Yuan B; Baysal MA; Chakraborty A; Andersen CR; Andersson BS
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
    Robert C; Nagaria PK; Pawar N; Adewuyi A; Gojo I; Meyers DJ; Cole PA; Rassool FV
    Leuk Res; 2016 Jun; 45():14-23. PubMed ID: 27064363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribosyl)ation of TIMELESS limits DNA replication stress and promotes stalled fork protection.
    Rageul J; Lo N; Phi AL; Patel JA; Park JJ; Kim H
    Cell Rep; 2024 Mar; 43(3):113845. PubMed ID: 38393943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Poly(ADP-Ribose) Polymerases 1 and 2: Classical Functions and Interaction with New Histone Poly(ADP-Ribosyl)ation Factor HPF1].
    Kurgina TA; Lavrik OI
    Mol Biol (Mosk); 2023; 57(2):254-268. PubMed ID: 37000654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins.
    Alemasova EE; Lavrik OI
    Nucleic Acids Res; 2019 May; 47(8):3811-3827. PubMed ID: 30799503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP1 is activated by membrane damage and is involved in membrane repair through poly(ADP-ribosyl)ation.
    Mashimo M; Kita M; Nobeyama A; Nomura A; Fujii T
    Genes Cells; 2022 Apr; 27(4):305-312. PubMed ID: 35124853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    Wiegmans AP; Yap PY; Ward A; Lim YC; Khanna KK
    Mol Cancer Ther; 2015 Oct; 14(10):2321-31. PubMed ID: 26294743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly-ADP ribosylation in DNA damage response and cancer therapy.
    Hou WH; Chen SH; Yu X
    Mutat Res Rev Mutat Res; 2019; 780():82-91. PubMed ID: 31395352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells.
    Wilson AJ; Holson E; Wagner F; Zhang YL; Fass DM; Haggarty SJ; Bhaskara S; Hiebert SW; Schreiber SL; Khabele D
    Cancer Biol Ther; 2011 Sep; 12(6):484-93. PubMed ID: 21738006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
    Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
    BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic insight into the role of Poly(ADP-ribosyl)ation in DNA topology modulation and response to DNA damage.
    Matkarimov BT; Zharkov DO; Saparbaev MK
    Mutagenesis; 2020 Feb; 35(1):107-118. PubMed ID: 31782485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Talazoparib enhances the quinacrine-mediated apoptosis in patient-derived oral mucosa CSCs by inhibiting BER pathway through the modulation of GCN5 and P300.
    Das C; Dash SR; Sinha S; Paul S; Das B; Bhal S; Sethy C; Kundu CN
    Med Oncol; 2023 Nov; 40(12):351. PubMed ID: 37940725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA maintenance following bleomycin-induced strand breaks does not require poly(ADP-ribosyl)ation activation in Drosophila S2 cells.
    Ishak L; Moretton A; Garreau-Balandier I; Lefebvre M; Alziari S; Lachaume P; Morel F; Farge G; Vernet P; Dubessay P
    DNA Repair (Amst); 2016 Dec; 48():8-16. PubMed ID: 27793508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
    Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
    BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
    Andronikou C; Rottenberg S
    Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.